Abstracts tagged "spondyloarthritis"

Abstract Number: L02 • ACR Convergence 2024
Persistent Articular Infection and Host Reactive Responses Contribute to Brucella-Induced Spondyloarthritis in SKG Mice
Jerome Harms¹, Jens Eickhoff¹, Thomas Warner¹ and Judith Smith², ¹University of Wisconsin-Madison, Madison, WI, ²University of Wisconsin, Madison, WI
Background/Purpose: Brucellosis, one of the most prevalent zoonotic diseases worldwide, often results in osteoarticular complications including large joint and axial arthritis mimicking spondyloarthritis (SpA). Greater…
Abstract Number: 0071 • ACR Convergence 2024
Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis
Jina Yeo¹, Min-Gang Kim², Hee Sung Kwon³, Mi Ryoung Seo¹, Hyo-Jin Choi¹, YunJae Jung⁴, Eun Young Lee⁵ and Han Joo Baek⁶, ¹Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ²Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁴Department of Microbiology, College of Medicine, Gachon University, Incheon, Republic of Korea, ⁵3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa
Background/Purpose: The interleukin (IL)-23/IL-17 pathway is central to axial spondyloarthritis (axSpA) pathogenesis, yet treatments targeting IL-23 show inconsistent effectiveness across spondyloarthritis subtypes. We hypothesized that…
Abstract Number: 0539 • ACR Convergence 2024
Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association with HLA-B27 in European and Ibero-American Populations: Data from the REGISPONSER and RESPONDIA Registries
Maria Angeles Puche-Larrubia¹, María Lourdes Ladehesa-Pineda², Pilar Font³, Rubén Burgos Vargas⁴, Percival Sampaio-Barros⁵, José Maldonado Cocco⁶, Anabela Barcelos⁷, Jordi Gratacos Masmitja⁸, Xavier Juanola⁹, Alejandro Escudero-Contreras³, Janitzia Vázquez Mellado⁴, Iván Arias-de la Rosa¹⁰, Eduardo Collantes-Estevez¹¹ and Clementina López Medina¹², ¹Reina Sofía University Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Department of Rheumatology, Hospital General de México and Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁶Rheumatology, Buenos Aires University School of Medicine, Buenos Aires, Argentina, ⁷Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁸University Hospital Parc Taulí, Sabadell, Spain, ⁹Department of Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁰Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ¹¹Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba 14012, Spain, ¹²Reina Sofia University Hospital, Cordoba, Spain
Background/Purpose: To date, few comparative studies have explored how ethnic and geographical differences impact the clinical presentation and management of Spondyloarthritis (SpA). Moreover, no studies…
Abstract Number: 0560 • ACR Convergence 2024
Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides
Iuliia Kononenko¹, Marius Bedei², Bjoern Buehring³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Bochum, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Herne, Germany, ³Bergisches Rheuma-Zentrum, Wuppertal, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany
Background/Purpose: The SARC-F is a self-report screening tool for sarcopenia (Sar) used to identify individuals at risk for poor functional outcomes [1]. The aim of this study was…
Abstract Number: 0590 • ACR Convergence 2024
Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
Sofia Ramiro¹, Corine Gaillez², Uta Kiltz³, Lianne S Gensler⁴, Chaitali Pisal⁵, Juergen Braun⁶ and Alexis Ogdie⁷, ¹Leiden University Medical Center, Bunde, Netherlands, ²Novartis Pharma AG, Basel, Switzerland, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Novartis Healthcare Private Limited, Hyderabad, India, ⁶Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…
Abstract Number: 1082 • ACR Convergence 2024
The Journey of a Patient with Psoriatic Arthritis: The Path from Diagnosis to Treatment
Feyza Nur Azman¹, Kadir Tanin², Efe Sacin², Enes Azman¹, Melike Rizaoglu¹, Ceren Uc¹, Beste Acar¹ and Serdal Ugurlu³, ¹Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, ³Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal disease associated with psoriasis. This study was conducted to investigate the diagnostic journey to PsA, exploring…
Abstract Number: 1460 • ACR Convergence 2024
Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Lou Kawka¹, Jacques-Eric Gottenberg², Jérôme Avouac³, OLIVIER BROCQ⁴, GILLES HAYEM⁵, Xavier Mariette⁶, Alain Meyer⁷, BENOIT FLACHAIRE⁸, OLIVIER FOGEL⁹, ARTHUR GANDIOLLE¹⁰, MANON LESTURGIE¹¹, JEAN-FRANCOIS KLEINMANN¹², Samira Ahmed Yahia¹³ and Thao Pham¹⁴, ¹Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁵Groupe Hospitalier Paris Saint-Joseph, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁷UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁸Aix Marseille University, Marseille, France, ⁹AP-HP, Paris, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Cochin hospital, Paris, France, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Hôpital Universitaire de Strasbourg, Strasbourg, France, ¹⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
Abstract Number: 2360 • ACR Convergence 2024
Patient Selection and Treatment Outcomes Using Preliminary Data-driven Definition versus the Established ASAS Definition of a Positive MRI of the Sacroiliac Joint in axSpA: Post-hoc Analysis from COAST-X
Xenofon Baraliakos¹, Victoria Navarro Compán², Pedro M. Machado³, Rebecca Bolce⁴, Hagen Russ⁵, Marcus Ngantcha⁶, Jeffrey Lisse⁶, Khai Jing Ng⁷, Sofia Ramiro⁸ and Denis Poddubnyy⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁴Eli Lilly and Company, Cincinnati, OH, ⁵Eli Lilly, Indianopolis, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Madrid, Spain, ⁸Leiden University Medical Center, Bunde, Netherlands, ⁹Charite-Universitatsmedizin Berlin, Berlin, Germany
Background/Purpose: To evaluate treatment outcomes based on the performance of a preliminary data-driven definition (PD) of a positive MRI of the SIJ in comparison to…
Abstract Number: 0072 • ACR Convergence 2024
The Association Between Activation of Inflammasome and HLA-B27 in Dendritic Cells of Patients with Axial Spondyloarthritis
Jina Yeo¹, Min-Gang Kim², Hye Eun Lee³, Yeonsoo Yang², Mi Ryoung Seo¹, Hyo-Jin Choi¹, Eun Young Lee⁴, Dae Ho Lee³ and Han Joo Baek⁵, ¹Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ²Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, ³Division of Endocrinology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ⁴3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa
Background/Purpose: Axial spondyloarthritis (axSpA) exhibits a predominant involvement of the innate immune system, marked by abnormal functions of innate immune cell such as dendritic cells…
Abstract Number: 0542 • ACR Convergence 2024
Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Clementina López Medina¹, Sofia Ramiro², Dafne Capelusnik³ and Anna Molto⁴, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Leiden University Medical Center, Bunde, Netherlands, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
Abstract Number: 0561 • ACR Convergence 2024
Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort
Annie Brink¹, Elisabeth Mogard², Elisabet Lindqvist², Jonas Sagard², Johan Karlsson Wallman¹ and Tor Olofsson², ¹Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden
Background/Purpose: A growing arsenal of biologic/targeted synthetic DMARDs often makes inflammation control an attainable target in axial spondyloarthritis (axSpA). Yet, many patients keep suffering from…
Abstract Number: 0591 • ACR Convergence 2024
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Jessica A Walsh¹, Joseph F. Merola², Christopher T Ritchlin³, Yoshiya Tanaka⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jason Coarse⁹ and William Tillett¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²UT Southwestern Medical Center, Dallas, TX, ³Allergy, Immunology & Rheumatology Division, University of Rochester Medical School, Rochester, NY, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁶National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Morrisville, NC, ¹⁰Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic disease, and patients (pts) can experience loss of response with sustained therapy; therefore, assessing long-term maintenance of response in pts…
Abstract Number: 1098 • ACR Convergence 2024
Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Antonio Avilés¹, Zulema Plaza², Fernando Sánchez-Alonso³, Santos Castañeda⁴, Benjamin fernandez-Gutierrez⁵, César Díaz⁶, Pilar Font⁷, Olga Martinez⁸, Emilio Giner⁹, José Miguel Senabre¹⁰, Amalia Rueda¹¹, Ana Perez¹², Gines Sanchez¹³, Carlos Gonzalez¹⁴, Javier García¹⁵, Javier Llorca¹⁶, Miguel Angel Gonzalez-Gay¹⁷ and Mariano Andres¹⁸, and CARMA project, reserch group., ¹Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Hospital Universitario de Salamanca, Zamora, Spain, ⁹Hospital Royo Villanova, Teruel, Spain, ¹⁰Hospital Marina Baixa Alicante, Alicante, Spain, ¹¹Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ¹²Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ¹³Hospital General de Albacete, Albacete, Spain, ¹⁴Hospital Universitario Lucus Augusti; Biodiscovery HULA-USC Group, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS., Lugo, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ¹⁷University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁸Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…
Abstract Number: 1461 • ACR Convergence 2024
Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center
Lourdes Martin-Sierra¹, Lara Sanchez Bilbao², Javier Rueda Gotor³, Vanesa Calvo-Rio⁴, Angela Egea-Fuentes⁵, Alba Herrero-Morant⁶, Inigo Gonzalez-Mazon⁷, Jose Ramon Muñoz-Rodriguez⁸ and Ricardo Blanco-Alonso⁹, ¹Hospital General Universitario de Ciudad Real, Ciudad Real, Castilla-La Mancha, Spain, ²Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Hospital Sierrallana, Torrelavega, Cantabria, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁶Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, ⁷H. U. Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Hospital General Universitario de Ciudad Real, Unidad de Investigación Traslacional de la Gerencia de Atención Integrada de Ciudad Real, Ciudad Real, Castilla-La Mancha, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Uveitis is a frequent extraarticular manifestation of axial Spondyloarthritis (axSpA), specifically anterior uveitis. Effects of biological therapy on uveitis associated to axSpA are poorly…

1
2
3
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].